TICKERNERD
Menu
BGLCBGLCBasic Materials · Specialty Chemicals

BGLC Stock Forecast: BioNexus Gene Lab Corp. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.19
0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 23 Oct 2026 — in the weakest quartile.

Market cap
$3.5M
Ticker Nerd rank
24/ 100
Median analyst target
—
Analysts covering
—
Revenue$76K−96.6% y/y
Operating income−$312K
Net income−$286K
Free cash flow−$423K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.5%
1M
−18.5%
YTD
−69.9%
1Y
−78.0%
From 52W high
−78.3%
From 52W low
0.0%
$1.19
$5.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BGLC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioNexus Gene Lab Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Oct 2026
24/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Accruals
89
Quality
35
Volatility
34
Growth
32
Issuance
29
Revisions
25
Value
23
Momentum
4

Size (96): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BGLC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BGLC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26BGLC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BGLC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

BGLC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, BioNexus Gene Lab Corp. returned −78.0% against +15.6% for the S&P 500, dividends included.

BGLC vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26BGLCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BGLC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

BioNexus Gene Lab Corp. (BGLC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 82% of US stocks

Price / sales
1.1×

Cheaper than 66% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
−0.1×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−96.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−96.6%

Higher than 2% of US stocks

Gross margin
17.0%

Higher than 17% of US stocks

Operating margin
−398.7%

Higher than 8% of US stocks

Net margin
−82.4%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−33.7%

Higher than 26% of US stocks

Return on assets
−19.0%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioNexus Gene Lab Corp. (BGLC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioNexus Gene Lab Corp. has a market value of $3.5M and an enterprise value of $292K.

  • Revenue in the twelve months to 30 June 2026: $3.1M. The latest quarter shrank 96.6% year on year.

  • Net income over the same four quarters: −$2.6M, a −82.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$854K.

  • Shares outstanding: 2.4M.

  • Trailing P/E: −0.7×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BioNexus Gene Lab Corp. employs 19 people — $165K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

BGLC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals
CompanyMarket capTKN rank
BGLCBioNexus Gene Lab Corp.$3.5M24
CNEYCN Energy Group, Inc.$3.9M20
SNESSenesTech, Inc.$4.5M37
YMATJ-Star Holding Co., Ltd.$8.2M12
BONBon Natural Life Ltd.$9.4M21
LOOPLoop Industries, Inc.$11.7M13
CITRCitroTech, Inc.$59.2M36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioNexus Gene Lab Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BGLC news & analysis

BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence

GlobeNewsWire · 7 Oct 2026positive

BioNexus will build AI applications for Malaysian healthcare under an exclusive CogniAI licence of up to 20 years, payable in shares. The excerpt also notes Malaysia’s commitment of RM1 billion to digitalizing public healthcare.

Why it matters — The licence and stated public-healthcare digitalization commitment provide context for BGLC’s planned healthcare AI work in Malaysia.

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

GlobeNewsWire · 28 July 2026positive

BioNexus announced continued progress toward commercializing its VitaGuard molecular residual disease platform in Southeast Asia following a working visit to Tongshu Gene facilities in China led by Fidelion's Chief Commercial Officer.

Why it matters — This indicates BioNexus is actively advancing the rollout of its VitaGuard MRD platform in the Southeast Asian market, a key strategic step for the company.

FAQ

Frequently asked questions about BGLC stock

How does Ticker Nerd's model rank BGLC?

As at 23 Oct 2026, BioNexus Gene Lab Corp. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the BGLC stock forecast for 2030?

No analyst covering BioNexus Gene Lab Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BGLC are extrapolating price history, which says nothing about the business.

How has BGLC stock performed over the past year?

BioNexus Gene Lab Corp. returned -78.0% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioNexus Gene Lab Corp. do?

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia.

What is the latest news on BGLC?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence". BioNexus will build AI applications for Malaysian healthcare under an exclusive CogniAI licence of up to 20 years, payable in shares. The excerpt also notes Malaysia’s commitment of RM1 billion to digitalizing public healthcare.

Company

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services. Through its subsidiaries, it supplies chemical raw materials used in industrial, medical, appliance, automotive, mechanical, and electronic manufacturing across Southeast Asia. BioNexus Gene Lab Corp. also develops blood-based diagnostic services that apply functional genomics and RNA analysis to support early disease detection and personalized health management. Its business model combines distribution of specialty materials with laboratory-focused healthcare solutions, positioning the company at the intersection of industrial supply chains and precision diagnostics. This mix gives BioNexus Gene Lab Corp. a role in both regional manufacturing markets and emerging molecular testing services.

CEO Mr. Su-Leng Tan · 19 employees · Malaysia · https://www.bionexusgenelab.com